CAMTA2 (Gene)

Synonyms:CAMTA2, ENTREZ:23125, HGNC:18807, MIM:611508, NM_001171166, NM_001171167, NM_001171168, NM_015099, NP_001164637, NP_001164638, NP_001164639, NP_055914, XM_006721478, XM_006721481, XM_006721482, XM_011523746, XM_011523747, XM_011523748, XM_011523749, XP_006721541, XP_006721544, XP_006721545, XP_011522048, XP_011522049, XP_011522050, XP_011522051, calmodulin binding transcription activator 2
Omim:OMIM:611508
Id:ENSG00000108509
Hgnc:HGNC:18807
Entrez:23125
Description:calmodulin binding transcription activator 2
The protein encoded by this gene is a member of the calmodulin-binding transcription activator protein family. Members of this family share a common domain structure that consists of a transcription activation domain, a DNA-binding domain, and a calmodulin-binding domain. The encoded protein may be a transcriptional coactivator of genes involved in cardiac growth. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Jan 2010]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CAMTA2's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CAMTA2.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CAMTA2.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CAMTA2.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CAMTA2.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.